<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039532</url>
  </required_header>
  <id_info>
    <org_study_id>BHI3</org_study_id>
    <nct_id>NCT01039532</nct_id>
  </id_info>
  <brief_title>Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Comparison of Thrice Daily Biphasic Human Insulin Versus Basal Detemir and Bolus Aspart in Patients With Poorly Controlled Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a proven fact that Basal Bolus insulin regimen is the near- physiological regimen &amp;&#xD;
      Thrice daily Biphasic Insulin Aspart is a comparable alternative for glycemic control in type&#xD;
      2 diabetes mellitus patients. In this study the investigators evaluated whether Biphasic&#xD;
      Human Insulin can be used in a thrice daily regimen in place of BIAsp.&#xD;
&#xD;
      As the regimen is less expensive and one prick less than the basal-bolus regimen, it can be a&#xD;
      good alternative for a diabetics in India.&#xD;
&#xD;
      This is a 12 week Open labelled parallel-Randomised controlled pilot study - 50 patients with&#xD;
      type 2 Diabetes mellitus was selected after satisfying the inclusion and exclusion criteria's&#xD;
      .Metformin and pioglitazone were continued and they are randomised into 2 groups at base line&#xD;
      and was allotted into any of the two regimens.&#xD;
&#xD;
        1. Basal detemir + bolus aspart or&#xD;
&#xD;
        2. Thrice Daily Biphasic Human Insulin Regimen.&#xD;
&#xD;
      The two regimens were compared by the following variables:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      Glycaemic control&#xD;
&#xD;
      Secondary endpoint:&#xD;
&#xD;
      Weight gain, Hypoglycaemic episodes, Adverse effects and Cost effectiveness&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a proven fact that Basal Bolus insulin regimen is the near- physiological regimen &amp;&#xD;
      Thrice daily Biphasic Insulin Aspart is a comparable alternative for glycemic control in type&#xD;
      2 diabetes mellitus patients. In this study the investigators evaluated whether Biphasic&#xD;
      Human Insulin can be used in a thrice daily regimen in place of BIAsp.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>3months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight gain Hypoglycaemic episodes Adverse effects Cost effectiveness</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Basal Bolus regimen</arm_group_label>
    <description>Basal Bolus regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biphasic human insulin</arm_group_label>
    <description>Biphasic human insulin</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        50 type 2 diabetes mellitus patients inadequately controlled patients treated with human&#xD;
        premixed insulin twice daily for at least 3months along with metformin 2g/d and&#xD;
        pioglitazone 30mg/d.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetics &gt;/= 18 yrs of age Diabetic for &gt;/= 6months&#xD;
&#xD;
          -  Inadequately controlled patients treated with human premixed insulin twice daily for&#xD;
             at least 3months along with metformin 2g/d and pio30mg/d&#xD;
&#xD;
               -  Single dose of insulin exceeding 25 units or total insulin dose is more than&#xD;
                  0.7u/kg/day with&#xD;
&#xD;
               -  If post lunch blood glucose is not controlled&#xD;
&#xD;
               -  If HbA1c â‰¥7%&#xD;
&#xD;
          -  No major cardiac events in the preceding 6 months.&#xD;
&#xD;
          -  NYHA &lt;= Class II.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Deranged LFT's- AST,ALT or ALP values &gt;= 2 times.&#xD;
&#xD;
          -  Deranged RFT Sr. Creatinine &gt;=1.5&#xD;
&#xD;
          -  Allergy to Insulin or its products.&#xD;
&#xD;
          -  Recent intake of any new medications for sugar control.&#xD;
&#xD;
          -  Illiterate to the level that she/he cannot understand the study.&#xD;
&#xD;
          -  Any other acute co morbid illness.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Decompensated heart failure/UsA/MI all within last 12month&#xD;
&#xD;
          -  Untreated proliferative retinopathy/ maculopathy&#xD;
&#xD;
          -  Drug or alcohol dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Bhansali, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AnilBhansali</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 24, 2009</study_first_submitted>
  <study_first_submitted_qc>December 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Anil Bhansali</investigator_full_name>
    <investigator_title>prof and head</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Biphasic human insulin thrice a day</keyword>
  <keyword>Basal bolus insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

